Press

PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch

Sep 7 • 4 min read

PharmaTher Holdings Ltd.(OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, announced today that it has completed an IND-enabling pharmacokinetic and tolerability study (the “Study”) of KETARX™ Ketamine Patch in minipigs. The KETARX™ Ketamine Patch was…

PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022

Sep 7 • 3 min read

PsyBio Therapeutics Corp. ( TSXV: PSYB | OTCQB: PSYBF), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announces that Evan Levine, Chief Executive Officer and Chairman, will present at the following upcoming conferences in September 2022: National…

Delic Announces Postponement of Meet Delic Conference

Sep 7 • 3 min read

Delic Holdings Corp (CSE: DELC | OTCQB: DELCF \ FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced the postponement of the Meet Delic conference taking place November 5 and 6 at AREA15 in Las Vegas, Nevada. The conference will now be held on October 14 and 15, 2023, in the same location. Tickets purchased for 2022…

Irwin Naturals Emergence to Add Ohio Ketamine Clinic

Sep 6 • 4 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) announced today that it has entered into a binding to agreement to acquire all of the membership interests in Happier You, LLC, which operates a ketamine clinic in central Ohio. This clinic will be added to Irwin Naturals Emergence, a fast-growing national chain of psychedelic mental-health clinics…

Core One Labs’ Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT

Sep 3 • 4 min read

Core One Labs Inc. (CSE:COOL | OTCQB:CLABF | Frankfurt:LD6 | WKN:A3CSSU) is pleased to announce that scientists at its wholly-owned subsidiary Awakened Biosciences Inc. (“Awakened”) have successfully completed the breakthrough first step in producing API N, N-dimethyltryptamine (DMT), with the synthesis of a DMT precursor. Awakened’s Chief Researcher, Dr. Tony Durst, has produced approximately 25 grams…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435